Aggressive Lymphomas
Conference Coverage
‘Impressive’ responses with nivolumab in relapsed Hodgkin lymphoma
Key clinical point:.
Conference Coverage
Daratumumab plus len-dex stalls myeloma progression in POLLUX trial
The anti-CD38 monoclonal antibody daratumumab added to lenalidomide/dexamethasone improved progression-free survival in relapsed/refractory...
News
Follicular lymphoma with histologic transformation may merit ASCT
Key clinical point: Histologic transformation of follicular lymphoma tends to occur early and may merit intensive salvage with autologous stem...
Conference Coverage
Mogamulizumab achieves objective responses in relapsed/refractory adult T-cell leukemia-lymphoma
Key clinical point: The anti-CCR4 monoclonal antibody mogamulizumab was superior to other investigator-selected therapies for the treatment of...
Conference Coverage
Alemtuzumab plus CHOP didn’t boost survival in elderly patients with peripheral T-cell lymphomas
Key clinical point: Adding the monoclonal anti-CD52 antibody alemtuzumab to CHOP (A-CHOP) increased response rates in elderly patients with...
News
FDA grants accelerated approval to nivolumab for Hodgkin lymphoma
News
Epstein-Barr virus DNA in plasma reliably detects EBV-positive lymphoproliferative disorders
Key clinical point: Epstein-Barr virus DNA was a more specific indicator of EBV+ diseases when detected in plasma, as opposed to peripheral blood...
News
Dose-escalated blinatumomab plus dexamethasone induced responses in relapsed/refractory DLBCL
Key clinical point: Stepwise dose-escalated administration of blinatumomab plus dexamethasone may be effective in patients with relapsed/...
News
FDG-PET guides need for eBEACOPP in advanced Hodgkin’s
Key clinical point: Using FDG-PET imaging to gauge treatment response after the first two rounds of ABVD therapy helps to determine which patients...
News
OTX015 dose for lymphoma narrowed in phase 1 study
Key clinical point: For lymphoma patients, a regimen has been determined for the small-molecule inhibitor OTX015 that was associated with...
News
Temsirolimus results in good but short-duration responses in primary CNS lymphoma
Key clinical point: Relapsed/refractory primary CNS lymphoma has a poor prognosis and no standard treatment option. Major finding: The overall...